On the stock market since 2003, it operates in the world of health and science. It has 10 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 6% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
An investor who bought at the very peak is down 73% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $5.4M a year. A small number, but proof the product has real buyers.
There is $40.7M in the vault; even if every debt were paid off, $40.5M would remain.
A loss of $12.1M against $5.4M in annual sales.
On our five-subject report card, ATHE sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ATHE is a high-risk stock — not yet profitable, and its future rides on its product catching on.